Breaking News

First Patient is Dosed with Triumvira’s Investigational TAC-T Cell Adoptive Immunotherapy

TAC01-HER2 was developed for the treatment of HER2-overexpressing cancers.

Author Image

By: Charlie Sternberg

Associate Editor

Lonza and Triumvira Immunologics announced that the first patient has been dosed with Triumvira’s investigational T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, in development for the treatment of HER2-overexpressing cancers.   Triumvira’s TAC01-HER2, which harnesses natural T cell activation, was manufactured on Lonza’s proprietary Cocoon Platform at C3i Center Inc in Montréal, Canada. The Cocoon Platform is an automated and closed platform for patient...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters